Work performed:
Based and expanding upon epSOS results, new use cases, and reviewing ISO/IDMP standards, the work performed identified a common structure, data elements and semantic assets (vocabulary) for the unambiguous definition, description, and identification of medicinal products (MPs) throughout Europe. Detailed exchanges with and contributions to the eHealth Network activities on revised Guidelines led to concrete solution proposals for rendering cross-border eHealth services (ePrescriptions, ePatient Summaries) safer and more efficient.
Four Expert Council Meetings were organised, twice at the premises of EMA in London, at CEN premises in Brussels, and with FDA at their premises in Washington, D.C.
Across all member states, a survey was undertaken to gather information on and to analyse the handling of concepts and practices of substitution of medicinal products at the point of dispensation.
A set of high level recommendations and a roadmap for post-project actions were discussed, validated and agreed.
Key results of openMedicine:
• A common data model for prescribed medicinal products (a common structure, data elements and semantic assets (vocabulary) for the unambiguous definition, description, and identification of medicinal products)
• Contributions to the activities of the eHealth Network and the revised Guidelines for ePatient Summaries and ePrescriptions.
• Submission of options to member states developing cross-border eHealth services in the context of the “Connecting Europe Facility” framework. In close cooperation with the EMA, intermediate solutions for univocally identifying medicinal products in cross-border contexts, particularly for ePrescribing services, were submitted
• Four Expert Council Meetings with representatives of all major player and stakeholder groups from both sides of the Atlantic, two at the premises of EMA in London, one at CEN facilities in Brussels, and one at the US Federal Drug Administration (FDA) in Washington, DC.
• An empirical surveyed across all member states on substitution of medicinal products at the point of dispensation.
• A set of high level, critical recommendations and a roadmap for post-project actions and implementations.
Dissemination:
Results were widely disseminated to key players, stakeholders, thought leaders and multipliers through Expert Council meetings, regional workshops all across the Union; presentations at conferences and standardisation bodies; publications; and a comprehensive website.
